Biopharma prediction markets are a small but expanding niche where participants bet on events like clinical trial outcomes and regulatory decisions. The idea is straightforward: traders buy and sell contracts tied to a drug's success or failure, and the market price reflects the collective probability as new information emerges.
Because these markets move on information, they create fresh avenues for insider knowledge to leak ahead of official disclosures. A trader with early access to unblinded data could profit before a trial's results are announced, raising questions about whether such behaviour crosses legal or ethical lines.
The same dynamic puts pressure on trial integrity. If market movements hint at outcomes mid-study, that could influence investigator behaviour or patient enrolment, potentially contaminating the very data the market is trying to predict. Regulators and sponsors are only beginning to grapple with these risks.
The single source notes the growth of the space and its dual concerns around insider information and trial integrity, but offers no countervailing view; the risks it flags remain largely unaddressed by existing oversight frameworks.